Publications
Featured Publications
Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors: ARTISTRY-1
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2022
- « Previous
- 1
- 2
All Publications
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Journal for ImmunoTherapy in Cancer (JITC)
November 2023
Modulation of IL-12p70 exposure and activity following sequential administration of tumor targeted self-assembling split IL-12 subunits
Society for Immunotherapy of Cancer (SITC)
November 2024
Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Society for Immunotherapy of Cancer (SITC)
November 2024
Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Society for Immunotherapy of Cancer (SITC)
November 2024
A Systematic Literature Review of Clinical Outcomes and Treatments in Post-Anti-PD-(L)1 Advanced Mucosal Melanoma from Interventional and Real-World Studies
Society for Melanoma Research (SMR) 2024
October 2024
Recommended Phase 2 Dose (RP2D) of Nemvaleukin Alfa in Patients With Advanced Solid Tumors Treated With Less Frequent Intravenous Dosing (ARTISTRY-3)
American Society of Clinical Oncology
June 2024
Interleukin-18 Engineered For Resistance to IL-18 Binding Protein (IL-18BP) and Half-Life Extension to Enhance Its Therapeutic Potential
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Generation of tumor targeted self-assembling split IL-12p35 and IL-12p40 subunits for the treatment of cancer
American Association for Cancer Research (AACR) Annual Meeting
April 2024
Assessment of Safety and Immunologic Activity of Nemvaleukin Alfa in Patients With Advanced Solid Tumors Treated With Less Frequent Intravenous Dosing (ARTISTRY-3)
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
Pattern of Natural Killer (NK) Cell (CD16+CD56+) Expansion Correlates With Response Outcomes With Nemvaleukin Alfa Treatment
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
Subcutaneous Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Refractory Solid Tumors (ARTISTRY-2)
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2023
Preliminary Pharmacodynamic Characterization in Patients With Platinum-Resistant Ovarian Cancer Treated With Nemvaleukin in Combination With Pembrolizumab
American Association for Cancer Research (AACR) Special Conference in Cancer Research: Ovarian Cancer
October 2023